**1. Introduction**

[3] Ronco C, Bredolan A, Crepaldi C, Rodighiero M, Scabardi M: Blood and dialysate flow distributions in hollow-fiber hemodialyzers analyzed by computerized helical

[4] Gastaldon F, Brendolan A, Crepaldi C, Frisone P, Zamboni S, d'Intini V, Poulin S, Hector R, Granziero A, Martins K, Gellert R, Inguaggiato P, Ronco C: Effects of novel manufacturing technology on blood and dialysate flow distribution in a new low flux "alpha Polysulfone" hemodialyzer. Int J Artif Organs. 2003 Feb;26(2):105-112 [5] Kim JC, Kim JH, Kim HC, Kim KG, Lee JC, Kang E, Kim HC, Min BG, Ronco C: Three-dimensional dialysate flow analysis in a hollow-fiber dialyzer by perfusion

[6] Külz M, Nederlof B, Schneider H: In vitro and in vivo evaluation of a new dialyzer.

[7] Leypoldt JK, Cheung AK, Agodoa LY, Daugirdas JT, Greene T, Keshaviah PR: He‐ modialyzer mass transfer-area coefficients for urea increase at high dialysate flow

[8] Golper TA, Ward RA: Dialysate... Ho-hum! Clin J Am Soc Nephrol. 2009 Sep;4(9):

rates. The Hemodialysis (HEMO) Study. Kidney Int. 1997 Jun;51(6):2013-7.

scanning technique. J Am Soc Nephrol 13: S53-S61, 2002

computed tomography. Int J Artif Organs. 2008 Jun;31(6):553-60.

Nephrol Dial Transplant (2002) 17: 1475-1479

1403-4. Epub 2009 Aug 20.

198 Updates in Hemodialysis

Options for renal replacement therapy (RRT) for patients with end-stage kidney disease (ESKD) include haemodialysis, peritoneal dialysis and renal transplantation. Although renal transplantation offers the best outcomes in terms of quality and quantity of life, most patients with ESKD will be treated with dialysis, either because they are ineligible for transplantation due to their burden of comorbid medical conditions, or because they commonly have to wait several years on dialysis before they are able to receive a kidney transplant. Survival of patients on dialysis remains poor, with reported annual mortality rates ranging from 12.7% in Australia and 14.6% for New Zealand [1] to 17.9% in Europe [2] to 25% in the United States of America [3]. Alternative ways of delivering dialysis that will materially improve patient outcomes are therefore required.

Emerging data suggest that haemodiafiltration (HDF), a form of haemodialysis that combines both diffusive and convective solute removal, may offer clinical benefits when compared to standard high-flux haemodialysis (HD). Despite these findings, the global uptake of haemo‐ diafiltration is variable and generally low, ranging from minimal use in the United States, 3.1% in the United Kingdom to 6% in Australia and 28.8% in Belgium [2]. This chapter will provide an overview of the principles and technical aspects of haemodiafiltration, as well as review the clinical evidence comparing HDF outcomes with those of HD.
